Skip to main content
Oxford University Hospitals NHS Foundation Trust

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Novel START (Novel Symbicort Turbuhaler Asthma Reliever Therapy)

Trial categories: Breathing

Sponsoring organisation: University of Oxford

This study is interested in investigating the effects of three different inhaler regimens in people with mild asthma.

The three regimens we are investigating are:

  1. Ventolin inhaler when you need it (Ventolin regimen)
  2. Symbicort inhaler when you need it (Symbicort regimen)
  3. Daily Pulmicort inhaler and Ventolin inhaler when you need it (Pulmicort and Ventolin regimen).

At the moment, we are unsure which regimen is most beneficial for people with mild asthma, which is why we are conducting this trial. We are interested in whether being on a different regimen influences:

  1. likelihood of having an asthma exacerbation
  2. asthma symptoms
  3. medication use.

Type of opportunity

Participation in clinical trial.

What will participants be asked to do?

The study runs for one year, during which participants would receive one of the following three regimens:

  1. Ventolin regimen
  2. Symbicort regimen
  3. Pulmicort and Ventolin regimen

The study involves at least seven visits to the research site (Churchill Hospital in Oxford or patient's local GP surgery if set up as a research centre for this trial).

Each visit is expected to take between 30 and 60 minutes apart from Visit 1 which may take up to two hours.

The study will also be running in a number of local GP surgeries and if the participant's local surgery is involved we may be able to arrange your follow-ups there if it's more convenient.

Who can take part?

Men and women with mild asthma who are aged between 18 and 75 years and use a single inhaler for their asthma.

Who is conducting the research?

Oxford Respiratory Trials Unit, University of Oxford based at the Churchill Hospital in Oxford.

Who has reveiwed the study?

South Central - Oxford B Research Ethics Committee and the Medicines and Healthcare products Regulatory Agency (MHRA).

How will the study benefit people with asthma?

There may be no direct clinical benefit to participants from the study as we are testing a new treatment regimen. However, clinical research mainly focuses on moderate to severe asthma, even though most adults with asthma have mild disease. This study will provide evidence to help guide clinical management of mild asthmatics and improve asthma guidelines. The information we get from this study may therefore help us to better treat patients with asthma in the future.

Participants will be provided with asthma education and inhalers for the duration of the study.

Expenses: Travel costs (up to £30.00 per visit) will be covered by the researchers.

What next/who to contact?

If you are interested in participating in this trial or would like to learn more, please contact:

Professor Ian Pavord:

or Anne McGahey, Research Nurse:

Back to list of trials

DEPARTMENTS AND SERVICES